Literature DB >> 2851351

Selective modulation by membrane potential of the interaction of some calcium entry blockers with calcium channels in rat mesenteric artery.

N Morel1, T Godfraind.   

Abstract

1. The effects of flunarizine, (+)-PN 200-110 and nifedipine on [3H]-(+)-PN 200-110 specific binding were investigated in intact rat mesenteric arteries bathed in physiological solution or in KCl-depolarizing solution, and in a membrane fraction from rat mesenteric arteries. 2. Unlabelled dihydropyridines, (+)-PN 200-110 and nifedipine, inhibited [3H]-(+)-PN 200-110 specific binding concentration-dependently in polarized as well as in depolarized intact arteries. The Ki value of (+)-PN 200-110 was decreased in arteries bathed in KCl-depolarizing solution compared to arteries bathed in physiological solution, while the Ki value of nifedipine was not significantly changed. Ki values measured in depolarized arteries were close to the IC50 values (concentrations inhibiting by 50% the KCl-contraction of rat mesenteric artery). 3. Flunarizine (10(-6) M) was unable to displace the specific binding of [3H]-(+)-PN 200-110 in intact arteries bathed in physiological solution. At 10(-7) M-10(-6) M, it inhibited the binding in depolarized arteries, suggesting that prolonged depolarization is required for the interaction of flunarizine with the dihydropyridine receptor. 4. In a membrane fraction isolated from rat mesenteric arteries, (+)-PN 200-110, nifedipine and flunarizine were all able to displace completely the specific binding of [3H]-(+)-PN 200-110. Displacement curves were parallel and Hill coefficients were close to unity. Ki values were close to the values obtained in depolarized intact arteries. 5. These results revealed a good correlation between the data obtained from binding tests and from pharmacological studies for dihydropyridine calcium entry blocking drugs, taking into account the time-dependence associated with their action on KCl-contraction compared to their binding properties. There was an important discrepancy between the concentrations of flunarizine active in binding studies and those active in pharmacological studies, which could be accounted for by the existence of multiple binding sites for calcium entry blockers in calcium channels.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2851351      PMCID: PMC1854141          DOI: 10.1111/j.1476-5381.1988.tb16571.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  A low voltage-activated, fully inactivating Ca channel in vertebrate sensory neurones.

Authors:  E Carbone; H D Lux
Journal:  Nature       Date:  1984 Aug 9-15       Impact factor: 49.962

3.  Changing surface charge with salicylate differentiates between subgroups of calcium-antagonists.

Authors:  M Spedding
Journal:  Br J Pharmacol       Date:  1984-09       Impact factor: 8.739

4.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.

Authors:  Y Cheng; W H Prusoff
Journal:  Biochem Pharmacol       Date:  1973-12-01       Impact factor: 5.858

5.  The inhibition by flunarizine of the norepinephrine-evoked contraction and calcium influx in rat aorta and mesenteric arteries.

Authors:  T Godfraind; D Dieu
Journal:  J Pharmacol Exp Ther       Date:  1981-05       Impact factor: 4.030

6.  Tissue heterogeneity of calcium channel antagonist binding sites labeled by [3H]nitrendipine.

Authors:  R J Gould; K M Murphy; S H Snyder
Journal:  Mol Pharmacol       Date:  1984-03       Impact factor: 4.436

7.  A unitary mechanism of calcium antagonist drug action.

Authors:  K M Murphy; R J Gould; B L Largent; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

8.  Actions of nifedipine on calcium fluxes and contraction in isolated rat arteries.

Authors:  T Godfraind
Journal:  J Pharmacol Exp Ther       Date:  1983-02       Impact factor: 4.030

9.  Characterization of binding of the Ca++ channel antagonist, [3H]nitrendipine, to guinea-pig ileal smooth muscle.

Authors:  G T Bolger; P Gengo; R Klockowski; E Luchowski; H Siegel; R A Janis; A M Triggle; D J Triggle
Journal:  J Pharmacol Exp Ther       Date:  1983-05       Impact factor: 4.030

10.  Dihydropyridine receptor in rat brain labeled with [3H]nimodipine.

Authors:  P Bellemann; A Schade; R Towart
Journal:  Proc Natl Acad Sci U S A       Date:  1983-04       Impact factor: 11.205

View more
  6 in total

1.  Dihydropyridine enantiomers block recombinant L-type Ca2+ channels by two different mechanisms.

Authors:  R Handrock; R Rao-Schymanski; N Klugbauer; F Hofmann; S Herzig
Journal:  J Physiol       Date:  1999-11-15       Impact factor: 5.182

Review 2.  Antioxidant effects and the therapeutic mode of action of calcium channel blockers in hypertension and atherosclerosis.

Authors:  Théophile Godfraind
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-12-29       Impact factor: 6.237

3.  Radioligand and functional estimates of the interaction of the 1,4-dihydropyridines, isradipine and lacidipine, with calcium channels in smooth muscle.

Authors:  S Salomone; T Godfraind
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

Review 4.  Cardioselectivity of calcium antagonists.

Authors:  T Godfraind
Journal:  Cardiovasc Drugs Ther       Date:  1994-05       Impact factor: 3.727

5.  Endothelin-1 and endothelin-2 initiate and maintain contractile responses by different mechanisms in rat mesenteric and cerebral arteries.

Authors:  M G Compeer; G M J Janssen; J G R De Mey
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

6.  Binding sites for 1,4-dihydropyridine Ca(2+)-channel modulators in rat intestinal smooth muscle.

Authors:  S Salomone; M Wibo; N Morel; T Godfraind
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-12       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.